Stocks · Korea
001360
KOSPI
Samsung Pharmaceutical
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
PER11.66x
PBR1.12x
EPS123 KRW
BPS1,286 KRW
ROE-13.05%
Dividend yield0.00%
DPS0 KRW
Payout ratio0.00%
Returns and 52-week range
1W+10.31%
1M+7.82%
3M+5.13%
6M-21.98%
1Y-14.69%
YTD-7.48%
52W high2,320원
52W low1,140원
From 52W high-38.19%
Financial results (separate)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 518억 | -140억 | -251억 | -26.9% |
| 2023 | 520억 | -180억 | -248억 | -34.7% |
| 2024 | 443억 | -148억 | -141억 | -33.5% |
| 2025 | 461억 | -181억 | 115억 | -39.2% |
| Quarterly | ||||
| 2024 4Q | 105억 | -29억 | -173억 | -27.6% |
| 2025 1Q | 114억 | -45억 | 372억 | -39.6% |
| 2025 2Q | 109억 | -43억 | 636억 | -39.5% |
| 2025 3Q | 120억 | -39억 | -302억 | -32.1% |
| 2025 4Q | 118억 | -54억 | -591억 | -45.8% |
| 2026 1Q | 90억 | -19억 | 88억 | -21.0% |
Company
Address: 경기도 화성시 향남읍 제약공단4길 10 -
Peers in the same sector
Recent filings
- 2026-09-02주요사항보고서(전환사채권발행결정) Major
- 2026-08-14반기보고서 (2026.06)
- 2026-08-12주요사항보고서(자기전환사채만기전취득결정) Major
- 2026-05-15분기보고서 (2026.03)
- 2026-03-18사업보고서 (2025.12)
- 2026-01-16주요사항보고서(전환사채매수선택권행사자지정) Major
- 2025-11-14분기보고서 (2025.09)
- 2025-08-20[기재정정]주요사항보고서(전환사채권발행결정) Major
- 2025-08-14반기보고서 (2025.06)
- 2025-08-14[기재정정]사업보고서 (2024.12)
Source: DART (Financial Supervisory Service electronic disclosure)
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.